Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29104 | 0.88 | MAPT (0.56) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL27356 | 0.85 | MAPT (0.53) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL23983316 | 0.84 | SIRT6 (0.54) | SIRT6ADRB1MAPTMEN1KMT2A | |
| SCHEMBL19221744 | 0.82 | MAPT (0.53) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL25845507 | 0.82 | MAPT (0.60) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL4714774 | 0.82 | MAPT (0.58) | SIRT6ADRB1MAPTMEN1KMT2A | |
| SCHEMBL19221745 | 0.82 | MAPT (0.53) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL10127676 | 0.82 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25845752 | 0.82 | SIRT6 (0.66) | SIRT6ADRB1MAPTHRH3MEN1 | |
| SCHEMBL27789 | 0.82 | MAPT (0.64) | SIRT6ADRB1MAPTHRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2025108404-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-120025326-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306706-A | Difunctional compound targeting androgen receptor protein degradation and application thereof | 上海壹迪生物技术有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BEONE MEDICINES I GMBH (CH) | 2024-07-25 | — | — | US | disclosed |
| WO-2009029998-A1 | RETROMETABOLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-12 | — | — | WO | disclosed |
| CN-101356159-A | Substituted isoquinoline-1, 3(2H,4H) -diones, 1-thio-1, 4-dihydro-2H-isoquinoline-3-ones and 1, 4-dihydro-3 (2H) -isoquinolones and their use as kinase inhibitors | WYETH CORP (US) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| EP-1373219-A1 | THIOHYDANTOINS AND USE THEREOF FOR TREATING DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| WO-2002081453-A1 | THIOHYDANTOINS AND USE THEREOF FOR TREATING DIABETES | LABORATOIRES FOURNIER SA (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | SIRT6 404/4885ADRB1 1869/4885MAPT 4860/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | SIRT6 2701/4885ADRB1 135/4885MAPT 4081/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | SIRT6 316/4885ADRB1 1692/4885MAPT 4865/4885 |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | SIRT6 2160/4885ADRB1 913/4885MAPT 4095/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | SIRT6 1752/4885ADRB1 4584/4885MAPT 3790/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | SIRT6 3721/4885ADRB1 1589/4885MAPT 3921/4885 |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BTK, CBL, SYK | SIRT6 2266/4885ADRB1 4159/4885MAPT 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.